Positive affect and negative affect constitute two broad general factors consistently identified as the dominant dimensions of emotional experience in inter-individual and intra-individual analyses across diverse descriptor sets, time frames, languages, and cultures.^[@R1]--[@R4]^ Positive affect, i.e. a state of pleasurable engagement with the environment eliciting positive emotions^[@R5],\ [@R6]^, has been shown to be associated with favorable psychological, physical, and economic outcomes in many longitudinal studies^[@R5]--[@R9]^. For instance, positive affect was a source of resilience for women having chronic pain^[@R7]^, buffer against risk for depression^[@R8]^, and protect against psychiatric symptoms in children exposed to natural disaster^[@R9]^. Further, a systematic review of longitudinal studies in healthy populations and populations with medical illness found that positive affect was associated with reduced mortality in both populations, independently of negative affect^[@R5]^. Moreover, a large U.S. representative longitudinal study found that young adults who reported higher positive affect went on to earn significantly higher income a decade later, even after the adjustment of potential confounders^[@R6]^.

Despite the many important impacts of positive affect, we still have very limited knowledge of its underlying biological mechanisms. Positive affect has a heritability of ≤64%^[@R10],\ [@R11]^, suggesting that genetic factors moderately contribute to this construct; however, the specific molecular loci contributing to this heritability remain to be identified. Hence, to elucidate genetic variants contributing to this phenotype, we performed a genome-wide association study (GWAS) of positive affect and a quasi-replication of our findings in positive affect in the realm of spiritual wellbeing in an independent cohort. Subsequently, we investigated functional significance of the identified genetic variants using brain and blood gene expression data and behavioral and neuroimaging data.

METHODS {#S1}
=======

The discovery sample {#S2}
--------------------

Participants in the discovery sample were recruited by the Grady Trauma Project (GTP) using the inclusion criteria of age ≥18, understanding English, and being able to give informed consent. Exclusion criteria included being acutely suicidal, psychotic, or having acute medical problems. Participants gave informed consent and the Institutional Review Boards of Emory University and Grady Memorial Hospital approved the study.

We assessed the trait-level positive affect with the Positive And Negative Affect Schedule (PANAS)^[@R12]^. Positive affect was represented by total score of the 10-item scale for positive emotional state (i.e. feeling interested, excited, strong, enthusiastic, proud, inspired, determined, attentive, and active). Each item was rated by participants using a 5-point scale ranging from *1=very slightly to not at all* to *4=quite a bit*, and *5=extremely* for the extent that they feel a particular positive emotion *in general*, that is, *on average*. The score ranges from 0--50, with higher score reflecting more positive affect. The PANAS has been validated in college students, other adults, and clinical populations and showed high internal consistency (Cronbach's α of 0.88), good stability over a two-month period (test-retest correlation of 0.68^[@R12]^), and substantial temporal stability over seven years (test-retest correlation of 0.42)^[@R13]^.

Childhood maltreatment was assessed with the well-validated Childhood Trauma Questionnaire^[@R14]^.

### Genotypes and principal components in the GTP discovery sample {#S3}

DNA was extracted from saliva or blood and genotyped on Illumina's Omni1-Quad BeadChip. We used Illumina's GenomeStudio to call genotypes and PLINK^[@R15]^ to perform quality-control (QC) analyses (see [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). We removed SNPs with call rates ≤98% or minor allele frequency (MAF) \<0.01, and individuals with \>2% missing data or having heterozygosity ≥2.5 standard deviations (SDs) away from the mean. We used PLINK to estimate the proportion of identity by descent (IBD) for each pair of individuals. Among pairs of individuals with an IBD \>0.12 (indicating cousins or a closer relation), we removed the individual in each pair with the higher rate of missing genotype data. Using autosomal data pruned in PLINK, we performed principal-component analysis (PCA) to infer axes of ancestry and remove outlier subjects. Based on PCA, we retained those African-American individuals who fell within three SDs of the medians of the first and second principal components (PCs) in our sample. After completion of QC and PCA, our sample consisted of 3728 African-American individuals genotyped for 883,511 SNPs. Of the individuals included in the genetic sample, 68% had positive affect data and were included in the GWAS (N=2522). We compared the N=2522 group with the N=3728 group and found that they had very similar distributions of the MAFs, demographic, and psychological characteristics ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) suggesting that the discovery sample was representative of the overall N=3728 sample.

### GWAS of positive affect in the discovery sample {#S4}

The positive affect score was transformed using the one-parameter Box-Cox transformation with a lambda value of 2 to increase normality^[@R16],\ [@R17]^. Using PLINK, we regressed the positive affect score on allele count assuming an additive model and included gender, childhood maltreatment total score, and the top 10 PCs as covariates. We use the commonly accepted genome-wide significance level of p\<5×10e-8^[@R18],\ [@R19]^.

cis-eQTL analysis for rs322931 using brain dataset {#S5}
--------------------------------------------------

The publicly accessible dataset from the UK Human Brain Expression Consortium (BRAINEAC; [braineac.org](http://braineac.org)), consists of post-mortem brain samples from 134 neuropathologically normal individuals of European descent^[@R20],\ [@R21]^. We examined the average gene expression across the ten available regions in this dataset: cerebellar cortex, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, temporal cortex, thalamus, and intralobular white matter. Affymetrix GeneChip Human Exon 1.0 ST arrays were used to obtain whole transcriptome profiling^[@R20]^. The QC process was previously described in detail^[@R20],\ [@R21]^. Expression data were corrected for gender and batch effects of hybridization date and brain bank prior to eQTL analyses.

Genomic DNA was extracted from brain tissues and genotyped on Illumina's Infinium Omni1-Quad BeadChip and ImmunoChip. After standard QC, both datasets were combined and only SNPs with good post-imputation quality (r^2^\>0.50) and MAF≥0.05 were included for analyses^[@R20],\ [@R21]^. For rs322931, only one subject had imputed genotype in this dataset.

We obtained exon-level and transcript-level probes for the genes located within 1 MB of rs322931 for *cis*-eQTL analysis^[@R21]^, in which the expression level was the outcome and rs322931 genotype the independent variable (using additive model). Bonferroni adjustment was used for multiple testing correction.

rs322931 vs. miR-181 in blood {#S6}
-----------------------------

RNA was extracted from whole blood of 68 GTP participants. Small RNA was size-fractionated from total RNA and then used as the starting material to generate small RNA libraries following the Illumina TruSeq® Small RNA protocol. Quality of the sequencing data was inspected with FastQC. Adapters were trimmed with Trimmomatic^[@R22]^. After trimming, sequences \<14 nucleotides were excluded. Trimmed reads were aligned to the miRBase v.21^[@R23]^ with SHRiMP aligner^[@R24]^, and only reads with a PHRED score ≥10 were considered for alignment. Percent reads mapped to mature miRNAs ranged from 81% to 98%, indicating high quality libraries and sequencing data. Among the 68 samples, one was an outlier with raw read counts 2.4 SDs below the mean and was excluded from the analysis. Counts of aligned miRNAs were normalized with regularized log-transformation using DESeq2^[@R25]^. The following miR-181a/b was extracted from this dataset: miR-181a-2-3p, miR-181a-3p, miR-181a-5p, miR-181b-2-3p, miR-181b-3p, and miR-181b-5p. Above 90% of the 67 samples had 0 abundance count for miR-181b-2-3p and miR-181b-3p, and 90% of the samples had counts ≤ 7 for miR-181a-3p; thus these three miRNAs were excluded from the eQTL analysis based on the threshold criteria for calling expressed miRNAs with high confidence^[@R23]^. eQTL analysis for the remaining three miR-181a and miR-181b was performed using linear regression, where the normalized expression of the miRNA was the outcome, genotype was the independent variable (additive model), and gender, the first genotypic PC, and batch were the covariates. Multiple testing was addressed with Bonferroni correction.

Functional MRI study {#S7}
--------------------

### Procedure {#S8}

55 women from the GTP cohort (2 TT, 16 TC, and 37 CC for rs322931) completed an MRI scan, as illustrated in [Figure 3](#F3){ref-type="fig"}. Two participants were excluded for falx calcification and eight due to excessive head motion (see below). The final sample for analysis included N=45: 2 TT, 12 TC, and 31 CC (demographics in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Participants viewed scene stimuli from the International Affective Picture Series^[@R26]^. Trials began with a white fixation cross, centered on a black background for a jittered inter-trial interval (ITI) of 1.5 -- 2.5 seconds. The scene was then presented for 1.5 seconds, followed by a rating period of 1.5 seconds. Scene stimuli were displayed in color full-screen at a resolution of 1024 × 768. The rating screen included a black background with "like / neutral / dislike" centered in white, 48pt Helvetica font. Thirty-six positive, 36 negative, and 36 neutral scenes were presented in a semirandom order such that no more than two pictures of the same valence preceded one another. Following scanning, participants reported subjective emotional arousal responses to each scene on a 1--5 scale (1-very little or no arousal, 5 - high arousal). Item order in the viewing and rating tasks was counterbalanced across participants.

### MRI acquisition {#S9}

Scanning took place on a 3.0T Siemens Trio with echo-planar imaging (EPI) (Siemens, Malvern, PA). T1-weighted scans were collected using 3D MP-RAGE with 176 contiguous 1 mm axial slices (TR/TE/TI = 2600/3.02/900ms, 1mm^3^ voxel size). Functional images were gathered using 37 3mm axial slices in a descending interleaved sequence (TR/TE =2000/3.00ms, 3mm^3^ voxel size).

### MRI preprocessing and analysis {#S10}

Initial data quality checks were performed using ArtRepair^[@R27]^. Slices containing spike artifacts were identified and replaced using linear interpolation, with no more than 4% of slices repaired per participant. Volumes affected by motion artifact were repaired using linear interpolation, with no more than 5% of volumes repaired per participant. Participants with head motion \> 1.5mm/TR in more than 5% of volumes were excluded from further analyses. Additional image preprocessing steps and statistical analyses were implemented in SPM8 (Wellcome Trust Centre for Neuroimaging). Volumes were slice-timing corrected to the middle slice in time, and spatially realigned to the first image of the run. A 128Hz high-pass filter removed low-frequency noise^[@R28]^. Segmented T1s and co-registered functional images were normalized to the Montreal Neurological Institute (MNI) template. Functional images were visually examined to verify that no participant had dropout in any substantial portion of the nucleus accumbens (NAc) or amygdala. Images were smoothed with a 6mm Gaussian kernel.

Task-related activity was modeled by convolving the onset times of scene stimuli in the positive, negative, and neutral emotion conditions with a canonical hemodynamic response function. First-level models included the 3 emotion conditions, and covariates for 6 rigid-body motion parameters. Contrasts of the Negative \> Neutral conditions, and Positive \> Neutral conditions from each subject were used in group-level random effects analyses. Genotype effects on emotion-related activation were investigated for rs322931. A dominance model was used to compare emotion-related activation in the CC group (N=31) to activation in T-carriers (TC, TT; N=14). Regions of interest (ROIs) were defined anatomically, using the masks from the IBASPM MaxPro MNI atlas^[@R29]^ (bilateral NAc), and probabilistic maps following Amunts et al^[@R30]^ (bilateral amygdala). Statistical significance levels for ROIs and exploratory whole-brain analyses were height-extent-corrected to a threshold of p\<0.05, using Alphasim Monte Carlo simulation with 1000 iterations for voxels within the NAc and amygdala ROIs, and a gray-matter mask created from the segmented MNI 152-subject average T1 for whole-brain analysis. With a cluster-forming threshold of p\<0.05, extents of k=5 for the NAc (voxel-wise p\<0.008) and k=18 for the amygdala (voxel-wise p\<0.003) were required for a corrected threshold of p\<0.05. Exploratory whole-brain analyses with a cluster-forming threshold of p\<0.01 required an extent threshold of k=25 to reach a corrected threshold of p\<0.05 (voxel-wise p\<0.0004). Subjective emotional arousal ratings were tested using a mixed-effects 3×2 ANOVA with emotion as a within-subjects predictor (positive, negative, neutral), and rs322931 group as between-subjects predictor (TT/TC vs. CC).

Fear-potentiated startle {#S11}
------------------------

Demographic data on the 248 GTP participants (14 TT, 87 TC, 147 CC for rs322931) who completed the fear-potentiated startle (FPS) task are shown in [Supplementary Table 7](#SD1){ref-type="supplementary-material"}. The FPS protocol was based off previous work^[@R31]^ shown to produce robust conditioning and consisted of a habitual phase, in which the conditioned stimuli (CSs) were presented without any reinforcement and a conditioning phase, which consisted of three blocks, each containing four presentations of each trial type, a reinforced CS (CS+), nonreinforced CS (CS−), and noise probe alone (NA). A response keypad was used during fear conditioning to record expectancies of the US on each CS presentation.

As previously described^[@R32]^, we measured the eyeblink component of the acoustic startle response by electromyography recordings of the right orbicularis oculi muscle. Data were acquired using Biopac MP150 for Windows and were filtered, rectified, and smoothed using MindWare software (MindWare Technologies, Ltd., Gahanna, OH). Startle magnitude was measured as the maximum amplitude of the eyeblink muscle contraction 20--200 ms after presentation of the startle probe. FPS was calculated by subtracting the mean startle magnitude for NA trials from the CS+ or CS− trials. A dominance model was used to compare the FPS to the CS+ (threat condition) and FPS to CS− (safety condition) in the CC group (N=147) to T-carriers (TC, TT; N=101).

Center for Health Discovery and Well Being (CHDWB) Replication Sample {#S12}
---------------------------------------------------------------------

The CHDWB was established to evaluate effectiveness and utility of a health and prevention-focused rather than disease-focused care setting. Inclusion criteria and exclusion criteria have been detailed previously^[@R33]^. Spiritual wellbeing was assessed with the FACIT Spiritual Well-Being scale, a well validated, 12-item scale measuring sense of inner peace, strength from spiritual beliefs, and sense of purpose in life in the past seven days^[@R34]^. Its score ranges from 0--48, with the higher score reflecting more spiritual wellbeing. The scale has been translated and validated in 15 different languages and used in many studies^[@R34]^. We included the two main ethnic groups, African American (N=103) and Caucasian (N=323) in the analysis, and excluded one American-Indian and 24 Asian-American individuals. Per dbSNP, rs322931 has similar MAF in African Americans (MAF=0.184) and Caucasians (MAF=0.183).

*Genotypes and PCs in the CHDWB:* DNA was extracted from blood and typed either on Illumina's OmniQuad or Core+Exome arrays to obtain genome-wide genotypes. SNPs with MAF \<0.01, with missing data in \>5% of the samples, and with Hardy-Weinberg Equilibrium (HWE) p-value \<10^−4^ were removed. Using PLINK^[@R15]^, we pruned the genome-wide autosome SNPs in 50-SNP-windows to remove all SNPs with linkage disequilibrium (LD) \>0.2, then we computed pairwise identity-by-state metrics, from which the multiple dimensional scaling was computed.

*Association between rs322931 and spiritual wellbeing* was examined with linear regression, in which genotype for rs322931 was the independent variable (using additive model), total score of spiritual wellbeing was the outcome, gender, and first four PCs as covariates.

RESULTS {#S13}
=======

2522 African-American participants, whose socio-demographic characteristics are presented in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}, were included in the GWAS. We found no evidence to suggest inflation of the association test statistics on the quantile-quantile plot after co-varying for 10 PCs, gender, and childhood maltreatment (genomic inflation factor λ=1.00; [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). We found two SNPs significantly associated with positive affect after gender, childhood maltreatment, and 10 PCs were adjusted for: rs322931 (β (SE)=60.3 (10.8), p=2.59×10^−8^) and rs7550394 (β (SE)=62.7 (11.4), p=3.84×10^−8^; [Figure 1A](#F1){ref-type="fig"}). The SNPs reside on chromosome 1 in a locus for LINC01221 and are in high LD with each other (D'=0.988 and r^2^ = 0.844). rs322931 and rs7550394 had a MAF of 0.19 and 0.17, and HWE p-value of 0.8 and 1, respectively. The SNPs are closest to miR-181a and miR-181b ([Figure 1B](#F1){ref-type="fig"}). The minor alleles of both SNPs were associated with having more positive affect. These two SNPs also met genome-wide significance level when we only adjusted for gender and 10 PCs (rs322931: β=61.6; p=3.86 × 10^−8^; rs7550394: β=64.4; p=4.73 × 10^−8^). Given their high degree of LD with each other, in follow-up studies, we focused on rs322931 for further analyses.

rs322931 is a brain cis-eQTL for miR-181a and miR-181b {#S14}
------------------------------------------------------

We next investigated if rs322931 is a *cis*-eQTL in the brain. There are six genes within 1 MB of rs322931: MIR181A, MIR181B, PTPRC, ATP6V1G3, NEK7, and NR5A2 ([Figure 1B](#F1){ref-type="fig"}). The six genes were represented by eight transcripts in the BRAINEAC dataset ([Table 1](#T1){ref-type="table"}). Among these transcripts, rs322931 was significantly associated with all four of the transcripts for miR-181a1 and miR-181b1, even after multiple testing correction (uncorrected p-values = \[1.30×10^−5^ to 6.60×10^−4^\]; Bonferroni adjusted p-values = \[1.04×^−4^ to 5.28×10^−3^\], ([Table 1](#T1){ref-type="table"})).

At the exon-level, there were eight probes for miR-181a1/b1 ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), of which six were significantly associated with rs322931 at uncorrected p-values ranging from 1.30×10^−5^ to 1.90×10^−3^. The minor allele of rs322931 was significantly associated with lower expression of miR-181a1 and miR-181b1 for all of these six probes. The top three of these six probes were exprID 2450057 (β=0.29±0.06; p=1.30×10^−5^; [Figure 2A](#F2){ref-type="fig"}), exprID 2450024 (β=0.22±0.06, p=1.40×10^−4^; [Figure 2B](#F2){ref-type="fig"}), and exprID 2450059 (β=0.20±0.05, p=1.40×10^−4^; [Figure 2C](#F2){ref-type="fig"}).

In our secondary analysis we found that rs7550394 was also significantly associated with all four of the transcripts for miR-181a1/b1, with p-values ranging from 9.10×10^−5^ to 3.30×10^−3^. Likewise, its minor allele was associated with decreased expression of miR-181a1 and miR-181b1.

rs322931 is a blood eQTL for miR-181b {#S15}
-------------------------------------

Since we found that rs322931 is a brain cis-eQTL for miR-181a/b, we examined the relationship between this SNP and miR-181a/b in peripheral whole blood. We found that rs322931 was significantly associated with miR-181b-5p after gender, age, population substructure, and batch effects were simultaneously adjusted for (β=0.19±0.07, p=0.0121, Bonferroni adjusted p=0.0363; [Figure 2D](#F2){ref-type="fig"}). The minor allele of rs322931 was associated with higher expression of miR-181b-5p ([Figure 2D](#F2){ref-type="fig"}).

Effects of rs322931 on neuroimaging and psychophysiological measures of emotion {#S16}
-------------------------------------------------------------------------------

To probe potential effects on systems-level neurobiology, we examined the rs322931 polymorphism in relation to brain and psychophysiological markers of emotional reactivity. In the fMRI task comparing positive versus neutral stimuli, T-allele carriers showed greater responses than those with CC genotype in the NAc ([Figure 4A](#F4){ref-type="fig"}) and amygdala ([Figure 4B](#F4){ref-type="fig"}) ROIs. No group differences were observed in the NAc and amygdala for negative versus neutral stimuli. Whole-brain analyses of T-carriers relative to the CC showed greater activation in the left putamen and caudate, left superior and middle frontal gyri, and left occipital cortex in response to both positive and negative stimuli, relative to neutral ([Figure 4C--D](#F4){ref-type="fig"}, [Supplementary Tables 5--6](#SD1){ref-type="supplementary-material"}). T-carriers showed less activation than CC for negative versus neutral stimuli in the left thalamus and in midbrain areas including the periaqueductal gray and substantia nigra. In sum, the minor allele of rs322931 was associated with greater fMRI activation of brain regions involved in emotion and reward.

In fear conditioning paradigm we found that T-carriers had less fear to the safety cue than CC group (p=0.025; [Figure 4E](#F4){ref-type="fig"}). The groups did not differ in their responses to the fear cue. This finding suggests that the minor allele of rs322931 is associated with better fear inhibition in response to safety cue.

Quasi-replication of rs322931 in positive affect in an independent cohort {#S17}
-------------------------------------------------------------------------

As spiritual wellbeing is a dimension of positive affect, we performed a quasi-replication of our GWAS finding in spiritual wellbeing in the CHDWB cohort. Among the 426 participants (295 women and 131 men), we found a significant association between rs322931 and spiritual wellbeing after gender and PCs were adjusted for (s (SE) = 1.28 (0.63); p=0.044). The minor allele of rs322931 was associated with having more spiritual wellbeing, consistent with our finding in the discovery sample.

Percent variance of positive affect explained by genome-wide common SNPs {#S18}
------------------------------------------------------------------------

Lastly, using GCTA software^[@R35]^ we estimated the proportion of variance of positive affect explained by genome-wide common SNPs (MAF ≥0.01) in the GTP discovery sample. We found that the common autosomal SNPs together explained 21.4% ± 14.6% of the variance of positive affect when 10 PCs were included as covariates at *p*-value of 0.07, and 21.5% ± 14.6% of the variance of positive affect when 10 PCs and gender were included as covariates at *p*-value of 0.07. Our large standard deviations and nearly significant p-values for the estimates are likely due to our relatively small sample size.

DISCUSSION {#S19}
==========

In a GWAS of positive affect we identified a novel SNP on chromosome 1, rs322931, whose minor allele was significantly associated with having more positive affect in the discovery sample and more spiritual wellbeing in an independent replication sample. Consistently, we found the minor allele of rs322931 significantly associated with increased fMRI activation of the NAc, a key brain region for pleasure, reward, and motivation, to positive emotional stimuli, and with better inhibition of fear during presentation of a safety cue in a human fear conditioning paradigm. Furthermore, rs322931 influences expression of miR-181a and miR-181b in the brain and miR-181b in blood, which is notable for several reasons. First, prior studies suggest that miR-181a is part of the reward neurocircuitry since its expression in hippocampal neurons is induced by cocaine and amphetamine and dopamine signaling^[@R36]^, and its expression in the NAc influences cocaine-induced additive behavior^[@R37]^. We postulate that rs322931 mediates positive affect via the reward neurocircuitry by influencing miR-181a expression. Second, miR-181a is strongly enriched in the synaptodendritic compartment of the NAc and influences synaptic plasticity through regulating glutamate receptor 2 subunit of AMPA-type glutamate receptors^[@R36]^. Hence, rs322931 can be inferred to mediate synaptic plasticity, a dynamic process that is important for learning and memory^[@R38]^, and its decline is associated with cognitive aging and age-related neurological disorders^[@R39]^. Such effects on plasticity may explain the finding that the minor allele of rs322931 was associated with better learning of the safety signal in the fear conditioning experiment. Third, miR-181a/b are intrinsic regulators of T-cell receptor sensitivity and signaling strength^[@R40],\ [@R41]^; thus, by influencing expression of miR-181a/b, the SNP rs322931 may have some influence on the immune system. Taken together, we postulate that rs322931 influences positive emotion via miR-181 and the nucleus accumbens and may also influence synaptic plasticity and immune functioning, consistent with the psychosomatic interplay among affect, neuroplasticity, and physical health observed in prospective epidemiological studies.

The minor allele of rs322931 was associated with having more positive affect and decreased expression of miR-181a/b in the brain but increased expression of miR-181b in the blood, which is consistent with adaptive effects of down-regulation of miR-181a/b in the brain and upregulation of miR-181b in the blood. For instance, patients with schizophrenia had up-regulated expression of miR-181b in the temporal cortex^[@R42],\ [@R43]^. Similarly, depressed mice had upregulated expression of miR-181a in the prefrontal cortex versus controls^[@R44]^. Likewise, overexpression of miR-181 in rat hippocampal neurons inhibited dendritic growth^[@R45]^ and decreased the size and number of dendritic spines^[@R36]^. In peripheral blood, PTSD patients had reduced expression of miR-181a/b versus controls^[@R46]^.

It is notable that rs322931 genotype influenced NAc and amygdala responses to positive stimuli but had no effect on responses to negative stimuli. These findings suggest potential differences in the genetic pathways contributing to positive and negative emotion traits. For disease models, the findings highlight that positive emotional traits do not simply reflect decreased negative emotion but may confer resilience to co-occurring negative mood or stress. However, given the observation that rs322931 minor allele predicted greater reactivity to both positive and negative stimuli in striatal clusters outside the NAc, additional research is needed to specifically probe the effects of positive versus negative stimuli on various aspects of reward-related circuitry. The minor allele of rs322931was also associated with lower activation to negative stimuli in the left thalamus, and in midbrain nuclei that play major roles in regulating arousal responses, whose lesion can block arousal-related potentiation of the acoustic startle responses^[@R47][@R48],\ [@R49]^. Down-regulation of midbrain activation in minor allele carriers may contribute to the decreased startle response to the CS− observed in the fear conditioning experiment. Moreover, conditioned safety signals such as the one used in this study have been shown to activate the NAc due to their having rewarding properties^[@R50]^.

We observed that the amygdala responded similarly to the NAc to positive stimuli but not to negative stimuli in the rs322931 T-carriers vs. CC group ([Figure 4](#F4){ref-type="fig"}). Specifically, the amygdala showed increased activation to negative stimuli while the NAc did not, perhaps because a 1:1 association between these regions is not expected. Indeed, previous fMRI studies have often shown some disconnect in the responses of the amygdala versus NAc to positive and negative outcomes^[@R51]^, and a meta-analysis observes a consistent co-activation of the NAc and amygdala across studies, but much stronger associations between NAc and regions including anterior cingulate, medial frontal gyrus, parahippocampal gyrus, and other aspects of the striatum^[@R52]^. Both the amygdala and NAc are directly connected with many cortical and subcortical regions, and it is likely that they may receive different regulatory inputs from regions such as the prefrontal cortex and hippocampus depending upon the task or context.

For the GWAS of positive affect, we included childhood maltreatment as a covariate in the regression model for two reasons. First, childhood is a sensitive developmental window period when upbringing experiences can powerfully shape emotional development and psychological functioning in adulthood^[@R53],\ [@R54]^. In our dataset, there is a significant inverse correlation between childhood maltreatment total score and positive affect score (p\<0.0001). Second, studies have shown that genetic variants can moderate one's susceptibility to environmental insults^[@R55],\ [@R56]^.

We examined rs322931 in relation to depression, PTSD symptoms, alcohol use, drug use, negative affect, and resilience in the GTP sample, adjusting for gender and population substructure. Rs322931 was not significantly associated with depression, PTSD, alcohol use, or drug use. However, its minor allele was significantly associated with having less negative affect (p=0.002) and having more resilience (p=0.0018), consistent with our positive affect finding ([Supplementary Table 8](#SD1){ref-type="supplementary-material"}).

Okbay and colleagues recently published a very large GWAS of subjective well-being, operationally defined as having life satisfaction or positive affect, in which they identified three SNPs meeting genome-wide significance level for subjective well-being^[@R57]^. Additionally, the authors listed the top 44 SNPs for subjective wellbeing and the top 30 SNPs for positive affect in particular from their meta-analyses of original, unimputed datasets, as well as the top 76 SNPs for subjective wellbeing from a meta-analysis of cohorts with imputed genotypes. Our GTP dataset has original, unimputed genotypes. We examined the top SNPs from Okbay meta-analysis of GWAS of unimputed datasets in our GTP sample. Of their top 30 positive affect SNPs, 15 were found in the GTP sample. Of these 15 SNPs, one, rs6581971 (on chromosome 12, Okbay p= 4.84×10^−6^), was significantly associated with positive affect in our GTP sample at uncorrected p-value of 0.007. Of the Okbay's top 44 SNPs for subjective wellbeing, nine SNPs were found in the GTP sample. Of these nine, one SNP, rs13102973 (on chromosome 4, Okbay p= 3.05×10^−6^) was significantly associated with positive affect at the uncorrected p of value of 0.0487. Next we examined the top 76 SNPs from Okbay's meta-analysis of imputed datasets in our GTP sample. Of Okbay's 76 top SNPs for subjective wellbeing, 5 SNPs were found in the GTP dataset but none was associated with positive affect at uncorrected p-value\<0.05. These observations may be due to three factors. First, our GTP participants were all African Americans compared to the majority of Caucasian participants in Okbay's GWAS. Second, the majority of the studies included in the Okbay's meta-analysis used one item, usually extracted from various scales, to assess subjective wellbeing or positive affect while ours used a 10-item, psychometrically validated positive affect scale. While the Okbay's GWAS has great power from their enormous sample size, our study may have more comprehensive and fine-grained assessment of positive affect. Third, our GTP discovery sample consisted of inner-city participants with high levels of stress and trauma exposure. Hence, positive affect in this context reflects positive emotions in the face of environmental adversity, which arguably allowed us to observe adaptive effects of polymorphisms that may not be observable in populations with lower trauma or stress exposure.

Our results should be interpreted in light of their limitations. First, the sample sizes for both the discovery and replication samples are relatively small. With relatively few studies on genetic underpinnings of positive emotions, we face the challenges of a nascent research area. Second, our replication is a quasi-replication since trait-level positive affect was assessed in the discovery sample and state-level spiritual wellbeing was used in the replication sample. Nevertheless, spiritual wellbeing represents positive affect specific to the dimensions of inner peace, sense of purpose in life, and strength from spiritual beliefs. Similar to positive affect, spiritual wellbeing has been shown to be associated with better quality of life (r=0.48), better life satisfaction (r = 0.318), and better physical wellbeing (r=0.47), and inversely associated with hopelessness (r=−0.55), anxious preoccupation (r=−0.49) and depression (r=−0.34)^[@R34]^. Notably, genetic factors influencing the expression of the different dimensions of psychological wellbeing have been shown to be largely shared, as reflected by the high estimates of genetic correlations among the different dimensions (ranging from 0.77--0.99)^[@R11]^.

Future studies are needed to replicate our findings and to deeply sequence the region around rs322931 to elucidate the causal genetic variants for positive emotions. Understanding the neurobiology of positive affect and emotional wellbeing may provide a complementary and powerful approach to the current predominant focus on the biology of psychopathology.
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![Genome-wide Association Study of Positive Affect Identifies SNP rs322931\
**a)** Manhattan Plot of the GWAS for positive affect (rs322931, p=2.59×10^−8^); the blue line denotes standard genome-wide corrected significance^[@R18]^ at the negative log~10~(5×10^−8^) = 7.3. **b)** Regional plot of SNP associations within 1 MB of rs322931 (purple triangle) on chromosome 1; plot generated with LocusZoom.](nihms800485f1){#F1}

![SNP rs322931 associates with levels of miR-181 in brain and blood\
The minor allele of rs322931 is significantly associated with lower expression of miR-181a1 and miR-181b1 in the brain for all six of their exon-level probes. Shown on the x-axis are the number of minor allele of rs322931 and on the y-axis log~2~ of level of expression for each of the top three exon-level probes of miR-181a1 and miR-181b1: **a)** exprID 2450057 (p=1.30×10^−5^); **b)** exprID 2450024 (p=1.40×10^−4^); and **c)** exprID 2450059 (p=1.40×10^−4^); **d)** The minor allele of rs322931 is significantly associated with higher expression of miR-181-5p in blood. Shown on the x-axis is the number of minor alleles of rs322931 and on the y-axis level of RNA expression of miR-181b-5p. Outliers are depicted as black dots and the median is the middle line in the box.](nihms800485f2){#F2}

![FMRI task measuring response to emotional scene stimuli\
**a)** Example trial structure during the scene-viewing task. **b)** Subjective arousal ratings, shown as the mean across participants for each emotion condition, by rs322931 genotype group. Emotion condition significantly influenced arousal ratings, F\[2,60\]=40.9, p\<0.001), and there was no effect of genotype or genotype\*emotion interaction (p-values \>0.10). Error bars represent 1 SE. **c)** Significant clusters of fMRI activation for positive relative to neutral scenes across the whole sample, p\<.05, corrected at the whole-brain level. **d)** Significant clusters of fMRI activation for negative relative to neutral scenes across the whole sample, p\<.05, corrected at the whole-brain level. FMRI activation clusters are overlaid on a representative single subject in MNI space, and axial slices are shown in neurological orientation. Positive and negative stimuli elicited greater fMRI activation than neutral stimuli in brain regions consistent with emotional arousal and regulation, including the bilateral amygdala, insula, medial prefrontal cortex (mPFC), and occipital cortex. Abbreviations: AMY=amygdala; OCC=occipital cortex; INS=insula, mPFC=medial prefrontal cortex.](nihms800485f3){#F3}

![Effect of SNP rs322931 genotype on fMRI responses to emotional scene stimuli\
In both the NAc **(a)** and amygdala **(b)** ROIs, rs322931 T-carriers showed a greater response than the CC group to positive stimuli (positive\>neutral; NAc: xyz=15,5,−14, Z=2.6, k=12; amygdala: xyz=36,−1,−32, Z=3.3, k=21). Bar graphs show mean contrast estimates across voxels within the bilateral anatomical ROI masks; error bars show one SE. Genotype did not influence the response to negative stimuli (negative\>neutral) in either ROI. Additional regions that showed group differences in the whole-brain analysis are shown in **(c)** for the positive\>neutral contrast, and **(d)** for the negative\>neutral contrast. For all fMRI results, significant clusters are overlaid on slices from a representative template brain in MNI space, in neurological orientation. **e)** Effect of rs322931 genotype (TT/TC vs. CC) on fear-potentiated startle (p\<0.05 marked with \*).](nihms800485f4){#F4}

###### 

Association between rs322931 and average gene expression across the ten brain regions for the six genes located within 1 MB of rs322931 (*cis*-eQTL) at the transcript-level ID.

  geneSymbol           marker           rsid       exprID     chr    start       stop        p-value
  -------------------- ---------------- ---------- ---------- ------ ----------- ----------- ----------
  MIR-181A1            chr1:199019855   rs322931   t2450056   chr1   198868041   198868274   1.30E-05
  MIR-181A1            chr1:199019855   rs322931   t2450058   chr1   198868449   198868844   1.40E-04
  MIR-181A1            chr1:199019855   rs322931   t2450054   chr1   198867434   198868019   2.30E-04
  MIR181A1, MIR181B1   chr1:199019855   rs322931   t2450000   chr1   198776723   198906548   6.60E-04
  NR5A2                chr1:199019855   rs322931   t2374126   chr1   199845845   200146534   6.30E-03
  NEK7                 chr1:199019855   rs322931   t2373736   chr1   197958385   198292204   1.20E-01
  ATP6V1G3             chr1:199019855   rs322931   t2449922   chr1   198492257   198510075   2.00E-01
  PTPRC                chr1:199019855   rs322931   t2373842   chr1   198519065   198726605   2.10E-01

LOC100131234 is identified as miR-181A in [pubmed.org](http://pubmed.org)
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